Cellectis S.A. (NASDAQ: CLLS)

Cellectis S.A., known by its ticker symbol CLLS, operates in the biotechnological industry with a focus on gene-editing technologies. The company's core business activities involve the development of allogeneic Chimeric Antigen Receptor T-cells (CAR T-cells) for immuno-oncology applications and gene-edited hematopoietic stem and progenitor cells (HSPC) for other therapeutic indications. Cellectis utilizes its proprietary technologies to produce cost-effective, "off-the-shelf" products that can be distributed worldwide.

Cellectis operates in the rapidly evolving field of gene-editing, where it has established a strong competitive position. The company's unique gene-editing technology, coupled with its portfolio of proprietary product candidates, sets it apart from its competitors. Cellectis' gene-edited CAR T-cell product candidates are designed to harness the power of the immune system to target and eradicate cancer cells. The company's primary products include UCART19, ALLO-501, ALLO-316, and ALLO-715, among others. These products are designed to target specific antigens, such as CD19, BCMA, and CD70, to treat various cancers and diseases.

Cellectis generates revenue through licensing agreements with major pharmaceutical companies, including AstraZeneca, Allogene, and Servier. Under these agreements, the company grants exclusive rights to develop and commercialize its gene-edited CAR T-cell product candidates for specific indications. These partnerships demonstrate the confidence that major players in the industry have in Cellectis' technology and product pipeline.

In terms of clinical development, Cellectis has a number of ongoing clinical trials. These include a Phase 1 clinical trial of UCART19 in patients with relapsed or refractory B-cell acute lymphoblastic leukemia (ALL) and non-Hodgkin's lymphoma (NHL). The company is also conducting a Phase 1 clinical trial of ALLO-501 in patients with relapsed or refractory multiple myeloma (MM). Additionally, Cellectis is conducting a Phase 1 clinical trial of ALLO-316 in patients with relapsed or refractory renal cell carcinoma (RCC).

Cellectis' TALEN gene editing platform enables the efficient and precise editing of genes, which is critical for the development of highly specific and effective gene-edited CAR T-cell product candidates. The company has also entered into a number of collaborations and agreements with other companies, including a research collaboration and exclusive license agreement with Iovance Biotherapeutics and a research collaboration and non-exclusive license agreement with Cytovia Therapeutics.